The prognostic values of thyroid disorders in predicting COVID-19 composite poor outcomes: A systematic review and meta-analysis.
COVID-19
Hypothyroidism
Prognosis
Thyroid disorder
Journal
Diabetes & metabolic syndrome
ISSN: 1878-0334
Titre abrégé: Diabetes Metab Syndr
Pays: Netherlands
ID NLM: 101462250
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
24
12
2021
revised:
27
02
2022
accepted:
15
03
2022
pubmed:
5
5
2022
medline:
15
6
2022
entrez:
4
5
2022
Statut:
ppublish
Résumé
In this meta-analysis, we aimed to evaluate the prognostic properties of thyroid disorder during admission on poor prognosis and factors that may influence the relationship in patients with COVID-19. A systematic literature search of PubMed, EBSCO, and CENTRAL was conducted from inception to August 27, 2021. The main exposure was unspecified and specified thyroid disorders-hypothyroidism or hypothyroidism. The outcome of interest was the COVID-19 composite poor outcome that comprises of severity, mortality, ICU admission, and hospitalization. There were 24,734 patients from 20 studies. Meta-analysis showed that thyroid disorder was associated with composite poor outcome (OR 2.87 (95% CI 2.04-4.04), p < 0.001; I On-admission thyroid disorder was associated with poor prognosis in COVID-19 patients.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
In this meta-analysis, we aimed to evaluate the prognostic properties of thyroid disorder during admission on poor prognosis and factors that may influence the relationship in patients with COVID-19.
METHODS
METHODS
A systematic literature search of PubMed, EBSCO, and CENTRAL was conducted from inception to August 27, 2021. The main exposure was unspecified and specified thyroid disorders-hypothyroidism or hypothyroidism. The outcome of interest was the COVID-19 composite poor outcome that comprises of severity, mortality, ICU admission, and hospitalization.
RESULTS
RESULTS
There were 24,734 patients from 20 studies. Meta-analysis showed that thyroid disorder was associated with composite poor outcome (OR 2.87 (95% CI 2.04-4.04), p < 0.001; I
CONCLUSION
CONCLUSIONS
On-admission thyroid disorder was associated with poor prognosis in COVID-19 patients.
Identifiants
pubmed: 35508091
pii: S1871-4021(22)00078-9
doi: 10.1016/j.dsx.2022.102464
pmc: PMC8930180
pii:
doi:
Types de publication
Journal Article
Meta-Analysis
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
102464Informations de copyright
Copyright © 2022 Diabetes India. Published by Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that there is no conflict of interest.
Références
EClinicalMedicine. 2020 Jul 04;24:100448
pubmed: 32766546
PLoS One. 2020 Aug 6;15(8):e0237130
pubmed: 32760107
Diabetes Metab Syndr. 2020 Sep - Oct;14(5):1429-1430
pubmed: 32755846
BMJ Evid Based Med. 2021 Jun;26(3):107-108
pubmed: 32934000
J Clin Endocrinol Metab. 2021 Jan 23;106(2):e926-e935
pubmed: 33141191
Mol Cell Endocrinol. 2021 Feb 5;521:111097
pubmed: 33278491
Front Cell Dev Biol. 2021 Jan 21;8:614030
pubmed: 33553149
Epidemiol Infect. 2020 Oct 14;148:e255
pubmed: 33050972
PLoS One. 2021 Jun 4;16(6):e0252799
pubmed: 34086837
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
Diabetes Metab Syndr. 2021 Nov-Dec;15(6):102312
pubmed: 34731819
Front Endocrinol (Lausanne). 2019 Jul 17;10:482
pubmed: 31379748
Adv Drug Deliv Rev. 2021 Mar;170:1-25
pubmed: 33359141
Endocr Res. 2021 Nov;46(4):170-177
pubmed: 34014139
Biometrics. 1994 Dec;50(4):1088-101
pubmed: 7786990
Compr Physiol. 2020 Sep 24;10(4):1277-1287
pubmed: 32969509
BMC Endocr Disord. 2021 May 27;21(1):111
pubmed: 34044831
Heliyon. 2020 Dec;6(12):e05712
pubmed: 33344794
J Thyroid Res. 2013;2013:481287
pubmed: 24106641
Intern Med J. 2020 Nov;50(11):1410-1412
pubmed: 33215834
Open Med. 2009;3(3):e123-30
pubmed: 21603045
Gerontology. 2019;65(1):1-8
pubmed: 30032140
J Endocrinol. 2012 Apr;213(1):25-36
pubmed: 22043064
Lancet Diabetes Endocrinol. 2020 Sep;8(9):739-741
pubmed: 32738929
Clin Nutr ESPEN. 2021 Oct;45:120-126
pubmed: 34620307
J Endocrinol Invest. 2021 Dec;44(12):2735-2739
pubmed: 34101132
Lancet Diabetes Endocrinol. 2021 Apr;9(4):197-199
pubmed: 33617779
Endocrinol Metab Clin North Am. 1994 Jun;23(2):379-86
pubmed: 8070428
Stat Med. 1993 Jul 30;12(14):1293-316
pubmed: 8210827
Nat Rev Microbiol. 2021 Mar;19(3):141-154
pubmed: 33024307
Curr Drug Targets. 2021;22(3):254-281
pubmed: 33081670
Int J Clin Pract. 2021 Jun;75(6):e14129
pubmed: 33655591
J Renin Angiotensin Aldosterone Syst. 2020 Apr-Jun;21(2):1470320320926899
pubmed: 32408793
J Clin Endocrinol Metab. 2021 Jan 23;106(2):e803-e811
pubmed: 33180932
J Endocrinol Invest. 2021 May;44(5):1031-1040
pubmed: 33140379
Front Endocrinol (Lausanne). 2020 Aug 18;11:565
pubmed: 33013686
Clin Chim Acta. 2013 Apr 18;419:15-8
pubmed: 23348571
Allergy. 2020 Jul;75(7):1730-1741
pubmed: 32077115
Crit Care. 2020 Jul 13;24(1):422
pubmed: 32660650
J Microbiol Immunol Infect. 2021 Feb;54(1):12-16
pubmed: 32425996
Front Endocrinol (Lausanne). 2021 Feb 19;11:623792
pubmed: 33679608
J Intern Med. 2020 Oct;288(4):410-421
pubmed: 32459372
Front Endocrinol (Lausanne). 2019 Jun 04;10:350
pubmed: 31214123
J Clin Endocrinol Metab. 2012 May;97(5):1554-62
pubmed: 22344200
Indian J Endocrinol Metab. 2020 Nov-Dec;24(6):532-536
pubmed: 33643870
PLoS One. 2020 Aug 21;15(8):e0237960
pubmed: 32822413
Ther Adv Cardiovasc Dis. 2016 Aug;10(4):192-202
pubmed: 26715125
Front Public Health. 2020 Nov 19;8:593256
pubmed: 33330336
Nephrol Dial Transplant. 2001 Sep;16(9):1799-806
pubmed: 11522861